Research groups
Collaborators
-
Patrik Rorsman
Professor of Diabetic Medicine
-
Jakob Knudsen
Novo Nordisk Postdoctoral Research Fellow (2015-2019)
-
David Hodson
Robert Turner Professor of Diabetic Medicine and Director (interim) of The Bukhman Centre for Research Excellence in Type 1 Diabetes
Benoit Hastoy
PhD
Diabetes UK RD Lawrence Research Fellow; Scientific Director of the Centre for Artificial Intelligence in Precision Medicine (CAIPM)
Diabetes researcher | Pancreatic beta-cell physiology | Type 2 diabetes genetics | Precision medicine
Research
My research focuses on understanding how genetic variation associated with type 2 diabetes alters the function of pancreatic islet, with a particular interest in the molecular and cellular mechanisms controlling insulin secretion from beta cells.
At the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), I established an independent research programme supported by a Diabetes UK R.D. Lawrence Research Fellowship. My work combines human genetics with functional studies in human beta-cell models and primary human pancreatic islets, using electrophysiology, live-cell imaging and molecular approaches to determine how diabetes-associated genes and genetic variants affect beta-cell physiology.
A central aim of my research is to bridge the gap between genetic association and biological mechanism. By identifying how genetic perturbations alter insulin secretion at the cellular level, I aim to uncover mechanisms that can be exploited therapeutically and contribute to more precise approaches to the treatment of type 2 diabetes.
More recently, as Scientific Director of the Centre for Artificial Intelligence in Precision Medicine (CAIPM), I contributed to an interdisciplinary programme using genetics and artificial intelligence to identify potential therapeutic targets for type 2 diabetes. My role focused particularly on the functional validation of candidate targets in human beta-cell models and pancreatic islets, and on investigating whether pharmacological modulation of these targets could restore beta-cell function.
My current research interests build on this work and centre on three closely connected questions:
- How do type 2 diabetes risk variants alter the cellular mechanisms controlling insulin secretion?
- Can human genetics be combined with detailed beta-cell physiology to identify causal and therapeutically actionable mechanisms?
- Can these insights be translated into strategies to preserve or restore beta-cell function and more broadly islet function in diabetes?
Research background
I trained initially in the molecular biology of insulin exocytosis during my PhD in Professor Jochen Lang's laboratory in Bordeaux, where I investigated the role of the SNARE protein VAMP2 in insulin granule exocytosis.
In 2012, I joined Professor Patrik Rorsman's group at the University of Oxford, where I developed expertise in pancreatic beta-cell electrophysiology and live-cell imaging. This included electrophysiological characterisation of the human beta-cell lines EndoC-βH1 and EndoC-βH2 and studies of the effects of type 2 diabetes-associated genes on beta-cell exocytosis.
I subsequently joined the groups of Professors Anna Gloyn and Mark McCarthy and the DIVA consortium, where I began integrating human genetics with cellular physiology. My work contributed to understanding the functional consequences of diabetes-associated variation in genes including PAM and SLC30A8.
In 2019, I was awarded a Diabetes UK R.D. Lawrence Research Fellowship to establish my independent research programme at OCDEM. The programme investigated the molecular mechanisms through which type 2 diabetes risk genes influence the secretory capacity of human pancreatic beta-cells.
This combination of human genetics, beta-cell physiology, electrophysiology and imaging continues to underpin my research, with the longer-term objective of translating genetic discoveries into mechanistic understanding and new therapeutic opportunities for type 2 diabetes.
Key publications
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.
Journal article
Umapathysivam MM. et al, (2026), Genome Med, 18
Electrophysiological Characterization of Inducible Pluripotent Stem Cell-Derived Human β-Like Cells and an SLC30A8 Disease Model.
Journal article
Jaffredo M. et al, (2024), Diabetes, 73, 1255 - 1265
Loss of ZnT8 function protects against diabetes by enhanced insulin secretion.
Journal article
Dwivedi OP. et al, (2019), Nat Genet, 51, 1596 - 1606
Electrophysiological properties of human beta-cell lines EndoC-βH1 and -βH2 conform with human beta-cells.
Journal article
Hastoy B. et al, (2018), Sci Rep, 8
Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic β-cells.
Journal article
Thomsen SK. et al, (2018), Nat Genet, 50, 1122 - 1131
A Central Small Amino Acid in the VAMP2 Transmembrane Domain Regulates the Fusion Pore in Exocytosis.
Journal article
Hastoy B. et al, (2017), Sci Rep, 7
Increased Expression of the Diabetes Gene SOX4 Reduces Insulin Secretion by Impaired Fusion Pore Expansion.
Journal article
Collins SC. et al, (2016), Diabetes, 65, 1952 - 1961
Recent publications
Structure et dynamique fonctionnelle du domaine transmembranaire de la protéine SNARE VAMP2 lors de l’exocytose
Thesis / Dissertation
Hastoy B., (2026)
Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.
Journal article
Umapathysivam MM. et al, (2026), Genome Med, 18
Comparison of "Continuous" and "End-ischemic" Approaches of Oxygenated Hypothermic Machine Perfusion for Pancreas Preservation.
Journal article
Elzawahry MAME. et al, (2026), Transplant Direct, 12
Mitochondrial movement in pancreatic alpha cells requires Miro2 and is regulated by glucose.
Journal article
Ekstrand MH. et al, (2026), J Biol Chem, 302
Ticking Differently: Elucidating Sexual Dimorphism in Human Aging through Metabolomics, Proteomics and Genomics.
Preprint
Xiao S. et al, (2025)
Roles for the long non-coding RNA Pax6os1/PAX6-AS1 in pancreatic beta cell function.
Journal article
Lopez-Noriega L. et al, (2025), iScience, 28
Semaphorin 3E alters the secretory function of pancreatic islet beta cells
Conference paper
Hastoy B. et al, (2025), DIABETIC MEDICINE, 42
Electrophysiological Characterization of Inducible Pluripotent Stem Cell-Derived Human β-Like Cells and an SLC30A8 Disease Model.
Journal article
Jaffredo M. et al, (2024), Diabetes, 73, 1255 - 1265
Semaphorin signalling alters the function of islet alpha and beta cells
Conference paper
Acreman S. et al, (2024), DIABETOLOGIA, 67, S211 - S211